Phase III study of avelumab in NSCLC starts
4 November 2015 | By Victoria White
Avelumab is an investigational fully human anti-PD-L1 IgG1 monoclonal antibody that potentially uses the body’s own immune system to fight cancer...
List view / Grid view
News
Tumour DNA in blood can be used to track cancers
4 November 2015 | By Victoria White
Scientists have shown that tumour DNA shed into the bloodstream can be used to track cancers in real time as they evolve and respond to treatment...
Allergan and Mimetogen to develop tavilermide for dry eye disease
4 November 2015 | By Victoria White
Tavilermide is differentiated from other investigational therapies in dry eye disease because it induces the production of mucin...
ESCMID calls for universal flu vaccination for healthcare works
4 November 2015 | By Victoria White
ESCMID believes that one vital tool to increase the adoption of flu vaccinations among healthcare professionals is to establish hospital-based league tables throughout Europe...
NICE recommends Ikervis in final draft guidance
4 November 2015 | By Victoria White
Ikervis has been recommended for the treatment of keratitis in adults with dry eye disease who have not responded to tear substitutes...
MHRA helps make dementia medicine packaging more user-friendly
4 November 2015 | By Victoria White
From June 2016, medicines for the treatment of dementia will include the days of the week clearly on the blister packs...
7th Global Healthcare Conference
3 November 2015 | By London Business School
The Future of Healthcare - striking a balance between patients, value and innovation. Monday 7 December 2015...
Results announced for two drug injectable regimen for HIV maintenance therapy
3 November 2015 | By Victoria White
Results from the study show that cabotegravir and rilpivirine were comparable in maintaining viral suppression rates to a three drug oral regimen...
Coulter Partners recruits two to Curetis NV Supervisory Board
3 November 2015 | By Coulter Partners
Coulter Partners was delighted to partner with German diagnostics company Curetis AG on two strategic supervisory board appointments and congratulates them on their recent IPO launch...
Wickham Laboratories announces new microbial identification service
3 November 2015 | By Wickham Laboratories
Introducing the MALDI Biotyper® for rapid microbial identification....
Black Swan Analysis short-listed for the TVBM 2015 Management Team of the Year Award
3 November 2015 | By Black Swan Analysis
Black Swan Analysis has just been short-listed for the “The Management Team of the Year Award” sponsored by NatWest and open to outstanding management teams in the Thames Valley...
GSK and Merck initiate Phase I trial of GSK3174998 with Keytruda
3 November 2015 | By Victoria White
The trial will evaluate GSK3174998 as monotherapy and in combination with Keytruda in patients with locally advanced, recurrent or metastatic solid tumours that have progressed after standard treatment...
Shire to acquire Dyax; expands HAE pipeline
3 November 2015 | By Victoria White
Shire has announced that it is to acquire Dyax, a company focused on the development of plasma kallikrein inhibitors for the treatment of hereditary angioedema, for approximately $5.9 billion...
Breakthrough Therapy Designation for Keytruda in advanced colorectal cancer
3 November 2015 | By Victoria White
This is the third Breakthrough Therapy Designation granted for Keytruda. The drug was previously granted breakthrough status for advanced melanoma and advanced non-small cell lung cancer (NSCLC)...
Bristol-Myers Squibb to acquire Cardioxyl Pharmaceuticals
3 November 2015 | By Victoria White
The acquisition will give Bristol-Myers Squibb full rights to Cardioxyl’s lead asset CXL-1427...
